Search Results

Sumitomo Pharma America, Inc. (SMPA) today announced the oral presentation of data from the ongoing Phase 1/2 first-in-human study of DSP-5336 in patients with relapsed or refractory acute leukemia at the European Hematology Association (EHA) 2024 Hybrid Congress.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.

Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron.

Sumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron.

Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate.

Sumitomo Chemical Co., Ltd. and Valent BioSciences LLC announced that Pace International LLC and its operations overseas will become part of AgroFresh Solutions, Inc., a well-established leader in the postharvest solutions space.

Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

Sumitomo Pharma Canada, Inc., announced that ORGOVYX®, an oral gonadotropin-releasing hormone receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer.

Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.